Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Accumulated Expenses (2017 - 2025)

Cue Biopharma (CUE) has disclosed Accumulated Expenses for 9 consecutive years, with $783000.0 as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 56.79% to $783000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $783000.0 through Dec 2025, down 56.79% year-over-year, with the annual reading at $783000.0 for FY2025, 56.79% down from the prior year.
  • Accumulated Expenses hit $783000.0 in Q4 2025 for Cue Biopharma, down from $1.9 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $5.2 million in Q1 2024 to a low of $783000.0 in Q4 2025.
  • Historically, Accumulated Expenses has averaged $3.0 million across 5 years, with a median of $3.0 million in 2023.
  • Biggest five-year swings in Accumulated Expenses: skyrocketed 83.19% in 2024 and later tumbled 66.73% in 2025.
  • Year by year, Accumulated Expenses stood at $2.0 million in 2021, then grew by 13.28% to $2.3 million in 2022, then dropped by 2.38% to $2.2 million in 2023, then fell by 18.34% to $1.8 million in 2024, then plummeted by 56.79% to $783000.0 in 2025.
  • Business Quant data shows Accumulated Expenses for CUE at $783000.0 in Q4 2025, $1.9 million in Q3 2025, and $1.5 million in Q2 2025.